Retro Biosciences, a longevity-focused startup backed by OpenAI CEO Sam Altman, has raised additional capital at a $1.8 billion valuation, the company announced Friday. The funding marks a significant milestone for the biotechnology firm, which is developing therapies aimed at slowing the aging process.
The new valuation catapults Retro Biosciences into the upper echelon of privately held longevity companies. The startup's mission to extend human healthspan has attracted substantial investor interest amid a broader boom in age-related research.
According to STAT News, the company's latest fundraising round underscores growing confidence in the commercial potential of longevity science. Retro Biosciences has not disclosed the exact amount raised or the full list of participating investors.
This fresh capital injection will likely accelerate the firm's research and development efforts. As competition in the longevity space intensifies, the funding positions the startup to potentially advance its pipeline of therapeutic candidates toward clinical trials.
Sam Altman's continued backing lends credibility to the venture, though skeptics question whether ambitious longevity goals can translate into scalable treatments. The company's scientific progress remains closely watched.